Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of AK2017 versus daily human growth hormone in children with growth hormone deficiency
CTR20263331Phase 3Active
- Sponsor
- Anke Bio
- Start
- Sep 2026
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of AK2017 in growth hormone deficiency (GHD), sponsored by Anke Bio. Started Sep 2026; status: active.
02
Drugs
AK2017
03
Conditions
growth hormone deficiency (GHD)
Beyond the preview
Go deeper on CTR20263331.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263331.